Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Oncolytic viruses as therapeutic cancer vaccines.

Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS.

Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103. Review.

2.

Arming oncolytic viruses to leverage antitumor immunity.

de Gruijl TD, Janssen AB, van Beusechem VW.

Expert Opin Biol Ther. 2015 Jul;15(7):959-71. doi: 10.1517/14712598.2015.1044433. Epub 2015 May 10. Review.

PMID:
25959450
3.

Oncolytic viruses and their application to cancer immunotherapy.

Chiocca EA, Rabkin SD.

Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015. Review. Erratum in: Cancer Immunol Res. 2014 Jul;2(7):699.

4.

Oncolytic Viruses in Cancer Treatment: A Review.

Lawler SE, Speranza MC, Cho CF, Chiocca EA.

JAMA Oncol. 2017 Jun 1;3(6):841-849. doi: 10.1001/jamaoncol.2016.2064. Review.

PMID:
27441411
5.

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Guo ZS, Liu Z, Bartlett DL.

Front Oncol. 2014 Apr 10;4:74. doi: 10.3389/fonc.2014.00074. eCollection 2014. Review.

6.

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.

Marchini A, Scott EM, Rommelaere J.

Viruses. 2016 Jan 6;8(1). pii: E9. doi: 10.3390/v8010009. Review.

7.

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

8.

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.

Schirrmacher V.

Expert Opin Biol Ther. 2015;15(12):1757-71. doi: 10.1517/14712598.2015.1088000. Epub 2015 Oct 5. Review.

PMID:
26436571
9.

Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.

Nguyen TL, Wilson MG, Hiscott J.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):153-9. doi: 10.1016/j.cytogfr.2010.03.002. Epub 2010 Apr 14. Review.

PMID:
20395162
10.

Oncolytic viruses as immunotherapy: progress and remaining challenges.

Aurelian L.

Onco Targets Ther. 2016 May 4;9:2627-37. doi: 10.2147/OTT.S63049. eCollection 2016. Review.

11.

Going viral with cancer immunotherapy.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC.

Nat Rev Cancer. 2014 Aug;14(8):559-67. doi: 10.1038/nrc3770. Epub 2014 Jul 3. Review.

PMID:
24990523
12.

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL.

Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Review.

13.

Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Granot T, Yamanashi Y, Meruelo D.

Mol Ther. 2014 Jan;22(1):112-22. doi: 10.1038/mt.2013.215. Epub 2013 Sep 12.

14.

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW.

Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953. Review.

15.

Targeting autophagy to enhance oncolytic virus-based cancer therapy.

Meng S, Xu J, Wu Y, Ding C.

Expert Opin Biol Ther. 2013 Jun;13(6):863-73. doi: 10.1517/14712598.2013.774365. Epub 2013 Mar 14. Review.

PMID:
23488666
16.

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL.

Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Review.

PMID:
25686121
17.

Evolution of oncolytic viruses: novel strategies for cancer treatment.

Atherton MJ, Lichty BD.

Immunotherapy. 2013 Nov;5(11):1191-206. doi: 10.2217/imt.13.123. Review. Erratum in: Immunotherapy. 2014 May;6(5):657-8.

PMID:
24188674
18.

Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.

Holay N, Kim Y, Lee P, Gujar S.

Front Immunol. 2017 Jul 13;8:800. doi: 10.3389/fimmu.2017.00800. eCollection 2017. Review.

19.

Advances in Therapeutic Cancer Vaccines.

Wong KK, Li WA, Mooney DJ, Dranoff G.

Adv Immunol. 2016;130:191-249. doi: 10.1016/bs.ai.2015.12.001. Epub 2016 Jan 19. Review.

PMID:
26923002
20.

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT.

Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17.

Supplemental Content

Support Center